AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

AMICUS THERAPEUTICS, INC.

Regulatory Filings Feb 2, 2021

Preview not available for this file type.

Download Source File

RW 1 tm214628d2_rw.htm RW

February 2, 2021

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C 20549

Application for Withdrawal of Registration Statement on Form S-3 (File No. 333-252566)

Ladies and Gentlemen:

Amicus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that its Registration Statement on Form S-3 (File No. 333-252566), originally filed with the Securities and Exchange Commission (the “Commission”) on January 29, 2021 (the “Registration Statement”), together with all exhibits thereto, be withdrawn, with such withdrawal to be effective as of the date hereof pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”).

The Company is requesting withdrawal of the Registration Statement because of a filing error relating to the EDGAR coding. The Registration Statement was incorrectly coded and filed as an “S-3,” whereas the Company intended the Registration Statement to be filed with the Commission with the code “S-3ASR.” The Company expects to promptly file a new registration statement with the code “S-3ASR” (the “New Registration Statement”). The Registration Statement was not declared effective by the Commission, and no securities were sold pursuant to the Registration Statement.

In accordance with Rule 457(p) under the Securities Act, the Company requests that all fees paid to the Commission in connection with the initial filing of the Registration Statement be credited for use in connection with the filing of the New Registration Statement and, to the extent applicable, future filings.

If you have any questions regarding the foregoing application for withdrawal, please telephone Ellen Rosenberg, Chief Legal Officer and Corporate Secretary of the Company, at (215) 921-7600.

Very truly yours,
AMICUS THERAPEUTICS, INC.
By: /s/ Ellen Rosenberg
Name: Ellen Rosenberg
Title: Chief Legal Officer and Corporate Secretary

Field: Page; Sequence: 1; Options: Last

Field: /Page

Talk to a Data Expert

Have a question? We'll get back to you promptly.